Phase 2 Study of Targeted Stereotactic Body Radiation Therapy to Treat Single Metastatic Progression in People With Oligometastatic Breast Cancer on Usual Drug Therapy

What this Trial Is About

Researchers are evaluating whether adding Stereotactic Body Radiation Therapy SBRT to the usual drug treatment can help people with oligometastatic breast cancer whose cancer has worsened in a single metastatic site. This phase 2 study focuses on patients who have had a sustained response to systemic therapy for at least 6 months but show isolated progression, aiming to see if this combined approach can prevent further worsening or spread of cancer. Participants will continue their current systemic drug therapy while receiving precisely targeted SBRT to the progressing metastatic lesion. The radiation treatment is delivered using image guidance, typically with doses such as 10 Gy over 3 sessions or 7-8 Gy over 5 daily sessions excluding weekends. Systemic therapy will be paused on radiation days and resumed afterward. This treatment is initiated within 8 weeks after baseline measurements. During the study, participants remain on their usual drug therapy and receive SBRT at the identified site of progression. Researchers will monitor progression-free survival three months after starting SBRT to assess treatment effect. Participants must provide informed consent and have good performance status. The study is sponsored by Memorial Sloan Kettering Cancer Center and runs from 2022 to 2026.

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer